NURS 5334 ADVANCED PHARMACOLOGY: QUIZ
AND CORRECT ANSWERS PLUS RATIONALE
GRADED A+ NEW UPDATE 2026-2027 UTA
97 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Apply pharmacokinetic and pharmacodynamic principles to predict drug interactions and individualize
therapy
2 Integrate pharmacogenomic data to optimize drug selection and dosing
3 Evaluate complex polypharmacy regimens for safety, efficacy, and potential adverse effects
4 Prescribe evidence-based pharmacotherapy for acute and chronic conditions across diverse populations
5 NURS 5334 Advanced Pharmacology
6 Quiz and Correct Answers plus Rationale Graded A+ New Update 2026
7 2027 UTA
8 Foundations of Advanced Pharmacology
9 Applied Advanced Pharmacology
10 Advanced Advanced Pharmacology
11 Advanced Pharmacology Review
ABSTRACT
This study document brings together 97 carefully worded exam questions drawn from NURS 5334
Advanced Pharmacology: Quiz and Correct Answers plus Rationale Graded A+ New Update
2026-2027 UTA, with the strongest emphasis placed on Apply pharmacokinetic and
pharmacodynamic principles to predict drug interactions and individualize therapy, Integrate
pharmacogenomic data to optimize drug selection and dosing, Evaluate complex polypharmacy
regimens for safety, efficacy and and potential adverse effects. Every item follows the wording style
and level of reasoning you meet in the real paper, and each one is paired with a clear rationale so
the correct choice is never a guess. Work through the set at your own pace, mark the questions
that slow you down, then come back to them until the reasoning feels automatic. Learners who
revise this way walk into the exam room recognising the pattern behind the questions instead of
meeting them for the first time. Keep going - steady, honest practice is what turns a difficult paper
into a comfortable pass.
Page 1
,Q1 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO PREDICT DRUG
INTERACTIONS AND INDIVIDUALIZE THERAPY
A patient with chronic kidney disease (CrCl 25 mL/min) is prescribed a drug that is
90% renally eliminated and has a narrow therapeutic index. Which
pharmacokinetic parameter is most critical to monitor to avoid toxicity?
A. Volume of distribution (Vd)
B. Half-life (t1/2) CORRECT
C. Bioavailability (F)
D. Protein binding
RATIONALE: In renal impairment, reduced clearance prolongs half-life, increasing risk of toxicity
for narrow therapeutic index drugs. Vd, bioavailability, and protein binding are less directly
affected by renal function, though protein binding may change in uremia.
Q2 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO PREDICT DRUG
INTERACTIONS AND INDIVIDUALIZE THERAPY
A patient with major depressive disorder and CYP2D6 poor metabolizer status is
started on fluoxetine. Which adjustment is most appropriate?
A. Increase the dose to achieve therapeutic effect
B. Switch to a non-CYP2D6 substrate antidepressant
C. Monitor for serotonin syndrome and consider dose reduction CORRECT
D. No adjustment needed; fluoxetine is a prodrug
RATIONALE: CYP2D6 poor metabolizers have reduced clearance of fluoxetine, leading to higher
plasma levels and increased risk of adverse effects, including serotonin syndrome. Dose
reduction or alternative therapy is warranted; fluoxetine is not a prodrug.
Page 2
,Q3 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO PREDICT DRUG
INTERACTIONS AND INDIVIDUALIZE THERAPY
Which of the following best explains why a beta-blocker is effective in reducing
mortality in heart failure with reduced ejection fraction (HFrEF)?
A. Increased myocardial contractility
B. Reduction in heart rate and sympathetic tone CORRECT
C. Direct vasodilation of coronary arteries
D. Inhibition of the renin-angiotensin-aldosterone system
RATIONALE: Beta-blockers improve outcomes in HFrEF by reducing heart rate, myocardial
oxygen demand, and sympathetic nervous system overactivity, which reverse adverse
remodeling. They do not increase contractility or directly dilate coronary arteries.
Q4 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO PREDICT DRUG
INTERACTIONS AND INDIVIDUALIZE THERAPY
A patient on warfarin is prescribed trimethoprim-sulfamethoxazole for a urinary
tract infection. Which intervention is most critical?
A. Increase warfarin dose to maintain INR
B. Monitor INR closely and adjust warfarin dose as needed CORRECT
C. Switch to a different antibiotic to avoid interaction
D. No action needed; interaction is minimal
RATIONALE: Trimethoprim-sulfamethoxazole inhibits CYP2C9, increasing warfarin's
anticoagulant effect and bleeding risk. Close INR monitoring and dose adjustment are essential;
switching antibiotics may be considered but monitoring is paramount.
Page 3
, Q5 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO PREDICT DRUG
INTERACTIONS AND INDIVIDUALIZE THERAPY
A patient with asthma is prescribed a long-acting beta-agonist (LABA) without an
inhaled corticosteroid. What is the primary concern?
A. Increased risk of asthma-related death CORRECT
B. Development of tolerance to LABA
C. Rebound bronchoconstriction
D. Increased risk of oral thrush
RATIONALE: LABAs used without inhaled corticosteroids are associated with an increased risk
of severe asthma exacerbations and asthma-related death. Current guidelines mandate
combination therapy with an inhaled corticosteroid.
Q6 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO PREDICT DRUG
INTERACTIONS AND INDIVIDUALIZE THERAPY
Which statement accurately describes the mechanism of action of SGLT2
inhibitors in heart failure?
A. They increase renal sodium and water excretion, reducing preload. CORRECT
B. They directly inhibit myocardial sodium channels.
C. They block aldosterone receptors, reducing afterload.
D. They increase myocardial contractility.
RATIONALE: SGLT2 inhibitors promote natriuresis and glucosuria, leading to reduced preload
and improved cardiac function. They do not directly affect myocardial sodium channels or
aldosterone receptors.
Page 4
AND CORRECT ANSWERS PLUS RATIONALE
GRADED A+ NEW UPDATE 2026-2027 UTA
97 QUESTIONS
TABLE OF CONTENTS
# TOPIC
1 Apply pharmacokinetic and pharmacodynamic principles to predict drug interactions and individualize
therapy
2 Integrate pharmacogenomic data to optimize drug selection and dosing
3 Evaluate complex polypharmacy regimens for safety, efficacy, and potential adverse effects
4 Prescribe evidence-based pharmacotherapy for acute and chronic conditions across diverse populations
5 NURS 5334 Advanced Pharmacology
6 Quiz and Correct Answers plus Rationale Graded A+ New Update 2026
7 2027 UTA
8 Foundations of Advanced Pharmacology
9 Applied Advanced Pharmacology
10 Advanced Advanced Pharmacology
11 Advanced Pharmacology Review
ABSTRACT
This study document brings together 97 carefully worded exam questions drawn from NURS 5334
Advanced Pharmacology: Quiz and Correct Answers plus Rationale Graded A+ New Update
2026-2027 UTA, with the strongest emphasis placed on Apply pharmacokinetic and
pharmacodynamic principles to predict drug interactions and individualize therapy, Integrate
pharmacogenomic data to optimize drug selection and dosing, Evaluate complex polypharmacy
regimens for safety, efficacy and and potential adverse effects. Every item follows the wording style
and level of reasoning you meet in the real paper, and each one is paired with a clear rationale so
the correct choice is never a guess. Work through the set at your own pace, mark the questions
that slow you down, then come back to them until the reasoning feels automatic. Learners who
revise this way walk into the exam room recognising the pattern behind the questions instead of
meeting them for the first time. Keep going - steady, honest practice is what turns a difficult paper
into a comfortable pass.
Page 1
,Q1 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO PREDICT DRUG
INTERACTIONS AND INDIVIDUALIZE THERAPY
A patient with chronic kidney disease (CrCl 25 mL/min) is prescribed a drug that is
90% renally eliminated and has a narrow therapeutic index. Which
pharmacokinetic parameter is most critical to monitor to avoid toxicity?
A. Volume of distribution (Vd)
B. Half-life (t1/2) CORRECT
C. Bioavailability (F)
D. Protein binding
RATIONALE: In renal impairment, reduced clearance prolongs half-life, increasing risk of toxicity
for narrow therapeutic index drugs. Vd, bioavailability, and protein binding are less directly
affected by renal function, though protein binding may change in uremia.
Q2 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO PREDICT DRUG
INTERACTIONS AND INDIVIDUALIZE THERAPY
A patient with major depressive disorder and CYP2D6 poor metabolizer status is
started on fluoxetine. Which adjustment is most appropriate?
A. Increase the dose to achieve therapeutic effect
B. Switch to a non-CYP2D6 substrate antidepressant
C. Monitor for serotonin syndrome and consider dose reduction CORRECT
D. No adjustment needed; fluoxetine is a prodrug
RATIONALE: CYP2D6 poor metabolizers have reduced clearance of fluoxetine, leading to higher
plasma levels and increased risk of adverse effects, including serotonin syndrome. Dose
reduction or alternative therapy is warranted; fluoxetine is not a prodrug.
Page 2
,Q3 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO PREDICT DRUG
INTERACTIONS AND INDIVIDUALIZE THERAPY
Which of the following best explains why a beta-blocker is effective in reducing
mortality in heart failure with reduced ejection fraction (HFrEF)?
A. Increased myocardial contractility
B. Reduction in heart rate and sympathetic tone CORRECT
C. Direct vasodilation of coronary arteries
D. Inhibition of the renin-angiotensin-aldosterone system
RATIONALE: Beta-blockers improve outcomes in HFrEF by reducing heart rate, myocardial
oxygen demand, and sympathetic nervous system overactivity, which reverse adverse
remodeling. They do not increase contractility or directly dilate coronary arteries.
Q4 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO PREDICT DRUG
INTERACTIONS AND INDIVIDUALIZE THERAPY
A patient on warfarin is prescribed trimethoprim-sulfamethoxazole for a urinary
tract infection. Which intervention is most critical?
A. Increase warfarin dose to maintain INR
B. Monitor INR closely and adjust warfarin dose as needed CORRECT
C. Switch to a different antibiotic to avoid interaction
D. No action needed; interaction is minimal
RATIONALE: Trimethoprim-sulfamethoxazole inhibits CYP2C9, increasing warfarin's
anticoagulant effect and bleeding risk. Close INR monitoring and dose adjustment are essential;
switching antibiotics may be considered but monitoring is paramount.
Page 3
, Q5 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO PREDICT DRUG
INTERACTIONS AND INDIVIDUALIZE THERAPY
A patient with asthma is prescribed a long-acting beta-agonist (LABA) without an
inhaled corticosteroid. What is the primary concern?
A. Increased risk of asthma-related death CORRECT
B. Development of tolerance to LABA
C. Rebound bronchoconstriction
D. Increased risk of oral thrush
RATIONALE: LABAs used without inhaled corticosteroids are associated with an increased risk
of severe asthma exacerbations and asthma-related death. Current guidelines mandate
combination therapy with an inhaled corticosteroid.
Q6 APPLY PHARMACOKINETIC AND PHARMACODYNAMIC PRINCIPLES TO PREDICT DRUG
INTERACTIONS AND INDIVIDUALIZE THERAPY
Which statement accurately describes the mechanism of action of SGLT2
inhibitors in heart failure?
A. They increase renal sodium and water excretion, reducing preload. CORRECT
B. They directly inhibit myocardial sodium channels.
C. They block aldosterone receptors, reducing afterload.
D. They increase myocardial contractility.
RATIONALE: SGLT2 inhibitors promote natriuresis and glucosuria, leading to reduced preload
and improved cardiac function. They do not directly affect myocardial sodium channels or
aldosterone receptors.
Page 4
